ACADIA to Host Conference Call and Webcast on Monday, November 5,2007, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Oct. 29, 2007—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will report its unaudited financial results for the third quarterended September 30, 2007 on Monday, November 5, 2007, after the U.S.financial markets close. ACADIA's management will host a conferencecall and webcast on Monday, November 5, 2007, at 5:00 p.m. EasternTime to discuss ACADIA's financial results and development programs.
The conference call may be accessed by dialing 866-203-2528 forparticipants in the U.S. or Canada and 617-213-8847 for internationalcallers (reference passcode 99836009). A telephone replay of theconference call may be accessed through November 19, 2007 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 54193185). The conferencecall also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archivedthere until November 19, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive mid-to-late stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at diseases with large unmetmedical needs, including schizophrenia, Parkinson's disease psychosis,sleep maintenance insomnia, and neuropathic pain. All of the drugcandidates in ACADIA's product pipeline emanate from discoveries madeusing its proprietary drug discovery platform. ACADIA's corporateheadquarters is located in San Diego, California and it maintainsresearch and development operations in both San Diego and Malmo,Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor RelationsThomas H. Aasen, Vice President andChief Financial Officer
(858) 558-2871
SOURCE: ACADIA Pharmaceuticals Inc.